Vascular disease prevention in patients with diabetes.
Prevention is the key to reducing the vascular sequelae of diabetes. Prevention starts with good glycaemic control and continues with a comprehensive programme of risk modification, such as lipid-lowering therapy, antihypertensive treatment, and improved lifestyle. With regard to lipid modification, agents such as statins may provide additional, non-lipid effects in both the diabetic and non-diabetic patient. This review discusses recent studies supporting risk reduction, available treatments, and recommendations applicable to the diabetic patient.
Gavin
J
J
Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, MD 20815, USA. kagansteven@yahoo.com
Kagan
S
S
D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003925:Diabetic Angiopathies / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications / Q000517:prevention & control; D006973:Hypertension / Q000150:complications / Q000517:prevention & control; D007333:Insulin Resistance; D008019:Life Style; D008955:Models, Cardiovascular; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications / Q000517:prevention & control
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors